In the case of obesity and T2DM, the Standards of Medical Care in Diabetes from the American Diabetes Association for 2022, for patients where the objective is weight reduction, recommends the use of pharmacological agents with evidence of weight loss, such as metformin, α-glucosidase inhibitors, SGLT-2i, GLP1-RA, and amylin mimetics (26). This evidence concerns the gene IAPP and obesity disorder.